Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Island Pharmaceuticals Ltd ( (AU:ILA) ) has issued an update.
Island Pharmaceuticals reported that it is progressing two well-advanced clinical-stage programs targeting infectious diseases, highlighted by the completion of its Phase 2a/b PROTECT clinical trial in dengue. Both assets are positioned for major market potential and may qualify for U.S. Priority Review Vouchers, while recent positive feedback from the FDA on the Animal Rule regulatory pathway and multiple near-term clinical, operational and regulatory catalysts could accelerate development timelines and enhance the company’s strategic value in the antiviral therapeutics space.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian clinical-stage biopharmaceutical company focused on developing treatments for infectious viral diseases. Listed on the ASX under the ticker ILA, the company is advancing two key programs aimed at addressing urgent viral threats, with a particular emphasis on dengue fever and other high-burden infectious diseases that present significant global health and commercial opportunities.
Average Trading Volume: 522,978
Technical Sentiment Signal: Buy
Current Market Cap: A$115.7M
Find detailed analytics on ILA stock on TipRanks’ Stock Analysis page.